TerraPower Isotopes will invest $450 million to build an actinium-225 (Ac-225) manufacturing facility in the Bellwether District of Philadelphia.
The project features a multiyear buildout, with current good manufacturing (cGMP) actinium-225 production slated to begin in 2029, the company said in a March 17 statement. Combined with recently expanded capacity at its existing facility in Everett, WA, the new site will increase the company's Ac-225 production capacity 20-fold, TerraPower said.
The company noted it evaluated more than 350 potential sites across the U.S. and conducted 49 site visits across eight metropolitan areas before selecting the Philadelphia location. Ac-225 is an alpha-emitting isotope used in radiopharmaceutical therapies to treat cancer.
